Globus Medical (GMED) vs iRhythm (IRTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Globus Medical (GMED) has outperformed iRhythm (IRTC) over the past year, gaining 25.2% versus a loss of 39.6%. Over five years, IRTC leads with a +47.6% price change compared with -2.3% for GMED. Globus Medical is the larger company by market cap ($10.02 billion vs $3.52 billion), about 2.8 times the size, while iRhythm is growing revenue faster (+26.2% vs +16.7%).
On valuation, Globus Medical trades at a lower forward P/E (13.8x vs 83.3x for iRhythm). Globus Medical converts more of its revenue into profit, with a net margin of 18.3% versus -6.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMED | IRTC |
|---|---|---|
| Share price | $74.65 | $106.70 |
| Market cap | $10.02B | $3.52B |
| 1-day change | +1.80% | +4.00% |
| YTD return | -14.50% | -39.87% |
| 1-year return | +25.23% | -39.57% |
| 5-year return | -2.33% | +47.60% |
| P/E ratio (TTM) | 19.14 | — |
| Forward P/E | 13.83 | 83.26 |
| EPS (TTM) | $3.90 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.94B | $747.14M |
| Revenue growth (YoY) | +16.65% | +26.24% |
| Net income (latest FY) | $537.87M | $-44.55M |
| Gross margin | 67.41% | 70.57% |
| Operating margin | 16.33% | -7.68% |
| Net margin | 18.30% | -5.96% |
| 52-week high | $101.40 | $212.00 |
| 52-week low | $56.66 | $100.70 |
| Distance from 52-week high | -26.38% | -49.67% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +35.19% | +63.01% |
| Average volume | 1.51M | 569.39K |
| Shares outstanding | 111.83M | 32.96M |
| Employees | 6,000 | 2,400 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Globus Medical is about 2.8 times larger than iRhythm by market value ($10.02B vs $3.52B).
- GMED has outperformed IRTC by 64.8 percentage points over the past year.
- Globus Medical is more profitable, keeping 18.3 cents of every revenue dollar as net income versus -6.0 cents for iRhythm.
- iRhythm grew revenue faster in its latest fiscal year (+26.24% vs +16.65%).
About Globus Medical
GMED stock →Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.
Health Care · Medical/Dental Instruments · 6,000 employees
About iRhythm
IRTC stock →iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.
Health Care · Medical/Dental Instruments · 2,400 employees
GMED vs IRTC FAQ
Which is bigger, Globus Medical or iRhythm?
Globus Medical (GMED) is larger, with a market capitalization of $10.02B compared with $3.52B for iRhythm (IRTC).
Which stock has performed better over the past year, GMED or IRTC?
GMED returned +25.23% over the past 12 months, compared with -39.57% for IRTC (price return, excluding dividends). Past performance does not predict future results.
Are Globus Medical and iRhythm in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.